Want to see ANIX full AI Analyst Report?
Total Valuation
Anixa Biosciences has a market cap or net worth of $111.26M. The enterprise value is $90.23M.
Market Cap$111.26M
Enterprise Value$90.23M
Share Statistics
Anixa Biosciences has 34,023,064 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding34,023,064
Owned by Insiders5.37%
Owned by Institutions0.50%
Financial Efficiency
Anixa Biosciences’s return on equity (ROE) is -0.72 and return on invested capital (ROIC) is -82.67%.
Return on Equity (ROE)-0.72
Return on Assets (ROA)-0.68
Return on Invested Capital (ROIC)-82.67%
Return on Capital Employed (ROCE)-0.83
Revenue Per Employee0.00
Profits Per Employee-2.21M
Employee Count5
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Anixa Biosciences is ―. Anixa Biosciences’s PEG ratio is 0.95.
PE Ratio―
PS Ratio0.00
PB Ratio8.84
Price to Fair Value8.84
Price to FCF-18.69
Price to Operating Cash Flow-15.43
PEG Ratio0.95
Income Statement
In the last 12 months, Anixa Biosciences had revenue of 0.00 and earned -10.93M in profits. Earnings per share was -0.34.
Revenue0.00
Gross Profit-36.00K
Operating Income-11.70M
Pretax Income-11.03M
Net Income-10.93M
EBITDA-10.99M
Earnings Per Share (EPS)-0.34
Cash Flow
In the last 12 months, operating cash flow was -7.12M and capital expenditures 0.00, giving a free cash flow of -7.12M billion.
Operating Cash Flow-7.12M
Free Cash Flow-7.12M
Free Cash Flow per Share-0.21
Dividends & Yields
Anixa Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.76
52-Week Price Change1.24%
50-Day Moving Average2.80
200-Day Moving Average3.29
Relative Strength Index (RSI)69.17
Average Volume (3m)204.54K
Important Dates
Anixa Biosciences upcoming earnings date is Mar 8, 2024, TBA (Confirmed).
Last Earnings DateMar 10, 2023
Next Earnings DateMar 8, 2024
Ex-Dividend Date―
Financial Position
Anixa Biosciences as a current ratio of 8.08, with Debt / Equity ratio of 1.27%
Current Ratio8.08
Quick Ratio8.08
Debt to Market Cap<0.01
Net Debt to EBITDA0.09
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Anixa Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Anixa Biosciences EV to EBITDA ratio is -12.10, with an EV/FCF ratio of -18.54.
EV to Sales0.00
EV to EBITDA-12.10
EV to Free Cash Flow-18.54
EV to Operating Cash Flow-18.54
Balance Sheet
Anixa Biosciences has $13.69M in cash and marketable securities with $184.00K in debt, giving a net cash position of $13.50M billion.
Cash & Marketable Securities$13.69M
Total Debt$184.00K
Net Cash$13.50M
Net Cash Per Share$0.40
Tangible Book Value Per Share$0.43
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Anixa Biosciences is $10.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$10.33
Price Target Upside227.00% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast19.64%